NASDAQ:IDXX IDEXX Laboratories (IDXX) Stock Price, News & Analysis $570.21 +9.83 (+1.75%) Closing price 10/26/2026 04:00 PM EasternExtended Trading$568.38 -1.84 (-0.32%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About IDEXX Laboratories Stock (NASDAQ:IDXX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IDEXX Laboratories alerts:Sign Up Key Stats Today's Range$557.94▼$571.7550-Day Range$504.70▼$566.7652-Week Range$500.61▼$769.98Volume528,141 shsAverage Volume518,689 shsMarket Capitalization$44.92 billionP/E Ratio40.10Dividend YieldN/APrice Target$731.00Consensus RatingModerate Buy Company Overview IDEXX Laboratories, Inc. (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions. IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software. Its products are used by animal hospitals and veterinary professionals to support clinical decision-making and ongoing patient care. The company also provides diagnostic and testing solutions for livestock, poultry, and dairy producers, as well as microbiology testing products for municipal, commercial, and residential water markets. Founded in 1983, IDEXX is headquartered in Westbrook, Maine, and serves customers internationally. Jay Mazelsky has served as the company’s president and chief executive officer since 2022.AI Generated. May Contain Errors. Read More IDEXX Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreIDXX MarketRank™: 4.492800622645 of 5 starsIDEXX Laboratories scored higher than 90% of companies evaluated by MarketBeat, and ranked 38th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingIDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 9 buy ratings, 6 hold ratings, and no sell ratings.Upside PotentialIDEXX Laboratories has a consensus price target of $731.00, representing about 28.2% upside from its current price of $570.21.Amount of Analyst CoverageIDEXX Laboratories has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IDEXX Laboratories' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.15% Earnings GrowthEarnings for IDEXX Laboratories are expected to grow by 12.15% in the coming year, from $14.81 to $16.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IDEXX Laboratories is 40.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.11.Price to Earnings Ratio vs. SectorThe P/E ratio of IDEXX Laboratories is 40.10, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.91.Price to Book Value per Share RatioIDEXX Laboratories has a P/B Ratio of 28.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IDEXX Laboratories' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.47% of the float of IDEXX Laboratories has been sold short.Short Interest Ratio / Days to CoverIDEXX Laboratories has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IDEXX Laboratories has recently decreased by 0.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIDEXX Laboratories does not currently pay a dividend.Dividend GrowthIDEXX Laboratories does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.22 News SentimentIDEXX Laboratories has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.Search Interest4 people have searched for IDXX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,172,172.00 in company stock.Percentage Held by Insiders0.79% of the stock of IDEXX Laboratories is held by insiders.Percentage Held by Institutions87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IDEXX Laboratories' insider trading history. Receive IDXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXX Stock News HeadlinesIDEXX Laboratories (IDXX) vs. ZTS and NEOG: Can Raised Guidance and Product Expansion Drive Further Earnings Growth?October 22, 2026 | insidermonkey.comIDEXX Laboratories (IDXX) Rebounds On Jefferies Support, Is It Still 20% Undervalued?October 21, 2026 | finance.yahoo.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.October 27 at 1:00 AM | Digest Publishing (Ad)IDEXX Laboratories (NASDAQ:IDXX) Stock Rated "Buy" in New Coverage at The Goldman Sachs GroupOctober 19, 2026 | americanbankingnews.comIDEXX Laboratories (NASDAQ:IDXX) Stock Price Target Cut by JPMorgan Chase & Co.October 18, 2026 | americanbankingnews.comIDEXX Laboratories climbs 3.3% as investors appear to refocus on growth drivers ahead of third-quarter resultsOctober 16, 2026 | quiverquant.comQQ3 Earnings Forecast for IDXX Issued By KeyCorpOctober 16, 2026 | americanbankingnews.comIDEXX Laboratories’ Q3 2026 Earnings: What to ExpectOctober 15, 2026 | barchart.comSee More Headlines IDXX Stock Analysis - Frequently Asked Questions How have IDXX shares performed this year? IDEXX Laboratories' stock was trading at $676.53 at the beginning of 2026. Since then, IDXX stock has decreased by 15.7% and is now trading at $570.21. How were IDEXX Laboratories' earnings last quarter? IDEXX Laboratories, Inc. (NASDAQ:IDXX) released its earnings results on Tuesday, August, 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The business's revenue was up 9.7% on a year-over-year basis. Read the conference call transcript. Who are IDEXX Laboratories' major shareholders? IDEXX Laboratories' top institutional investors include Montrusco Bolton Investments Inc. (0.40%), Assenagon Asset Management S.A. (0.33%), Congress Asset Management Co. (0.22%) and Vontobel Holding Ltd. (0.16%). Insiders that own company stock include Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Michael Lane, Sharon E Underberg, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin. View institutional ownership trends. How do I buy shares of IDEXX Laboratories? Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IDEXX Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include NVIDIA (NVDA), Tesla (TSLA), Salesforce (CRM), PayPal (PYPL), Trade Desk (TTD), Walt Disney (DIS) and Adobe (ADBE). Company Calendar Last Earnings8/04/2026Today10/27/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IDXX's financial health is in the Red zone, according to TradeSmith. IDXX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IDXX CIK874716 Webwww.idexx.com Phone(207) 556-0300Fax207-556-4346Employees11,000Year Founded1983Price Target and Rating Average Price Target for IDEXX Laboratories$731.00 High Price Target$823.00 Low Price Target$665.00 Potential Upside/Downside+28.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$14.22 Trailing P/E Ratio40.10 Forward P/E Ratio38.50 P/E GrowthN/ANet Income$1.06 billion Net Margins25.03% Pretax Margin31.28% Return on Equity71.96% Return on Assets33.60% Debt Debt-to-Equity Ratio0.19 Current Ratio1.17 Quick Ratio0.87 Sales & Book Value Annual Sales$4.30 billion Price / Sales10.44 Cash Flow$15.35 per share Price / Cash Flow37.15 Book Value$20.10 per share Price / Book28.37Miscellaneous Outstanding Shares78,780,000Free Float78,159,000Market Cap$44.92 billion OptionableOptionable Beta1.55 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:IDXX) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IDEXX Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IDEXX Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
